a public good project by the
Synthesis
Company
of California

© 2026

Peter Brossart | doi.page

0 works0 citations0 h-index

Peter Brossart

University Hospital Bonn(DE)Integrated Oncology (United States)(US)

Publications by Year

Research Areas

Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, CAR-T cell therapy research, Chronic Myeloid Leukemia Treatments

Most-Cited Works

→ Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids(2000)645 cited
→ Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells(2000)539 cited
→ G-quadruplexes: a promising target for cancer therapy(2021)523 cited
→ Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation(2014)395 cited
→ Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial(2016)387 cited
→ The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo(2013)337 cited

→ Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants(2017)328 cited

→ Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies(1999)297 cited

→ Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses(2008)283 cited

→ Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells(2003)277 cited